About Gain Therapeutics, Inc. - Common Stock (GANX)
Gain Therapeutics Inc is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases. Utilizing its proprietary platform technology, the company aims to identify and optimize small molecules that can enhance protein function and restore the activity of misfolded proteins implicated in various disorders. By leveraging insights from structural biology and drug design, Gain Therapeutics seeks to improve treatment outcomes for patients suffering from conditions such as Alzheimer's and Parkinson's disease, potentially reshaping the landscape of therapeutic options in the field of neurology. Read More
Gainers Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market session. The market value of their outstanding shares is at $74.6 million. BNB Plus (NASDAQ:BNBX) stock rose 9.78% to
BETHESDA, Md., June 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in a virtual fireside chat and one-on-one meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, being held in a hybrid format from June 15-16, 2026.
BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update.
BETHESDA, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral presentation at the 3rd International GBA1 Meeting 2026, being held May 22-23, 2026, in Phoenix, AZ.
BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update.
BETHESDA, Md., March 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in a fireside chat and one-on-one meetings at the 38th Annual ROTH Conference, being held March 22-24, 2026, in Dana Point, CA.
Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals with high baseline CSF glucosylsphingosine
BETHESDA, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s management team will participate in a fireside chat and one-on-one meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held Wednesday, February 25th through Thursday, February 26th.
BETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced its attendance at conferences during the week of the 44th Annual J.P. Morgan Healthcare Conference (“JPM week”) including at the Sachs Neuroscience Innovation Forum, the Demy-Colton/Informa Biotech Showcase™, and the LifeSci Advisors Corporate Access Event.
Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint
Presented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical models in vivo and the proposed mechanism of action
BETHESDA, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation at the Society for Neuroscience annual meeting, Neuroscience 2025, being held November 15th–19th in San Diego, CA.
BETHESDA, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it will participate in the upcoming 2025 Maxim Growth Summit, taking place from October 22nd to 23rd at The Hard Rock Hotel NYC.
